文献速递淋巴瘤白血病

Moxetumomab pasudotox治疗毛细胞白血病:从临床前开发到FDA批准

Moxetumomab pasudotox for hairy cell leukemia: preclinical development to FDA approval.
PubMed 文献 · Blood Adv · 2019-01-01

Moxetumomab pasudotox(MP)是一种靶向CD22的重组免疫毒素,获FDA批准用于至少接受过2线治疗(包括嘌呤类似物)失败的毛细胞白血病(HCL)。关键III期试验显示持续完全缓解率为30%,85%的完全缓解者达到微小残留病阴性。MP免疫抑制作用较嘌呤类似物弱,但具有毛细血管渗漏综合征和溶血性尿毒症综合征等独特毒性。

要点

  • MP获批用于至少2线治疗失败(含嘌呤类似物)的HCL。
  • 关键III期试验持续完全缓解率30%,85%完全缓解者MRD阴性。
  • MP有毛细血管渗漏综合征和溶血性尿毒症综合征等独特毒性。

核心结论

  • MP对复发/难治性HCL具有深度且持久的缓解,持续完全缓解率达30%,85%完全缓解者达MRD阴性。

研究设计与样本

  • 本综述涵盖MP的临床前与临床开发,重点讨论其在HCL中的当前适应证。
  • 关键III期试验在复发/难治性HCL患者中评估MP。

主要发现

  • 关键III期试验显示持续完全缓解率为30%,85%的完全缓解者达到MRD阴性。
  • MP免疫抑制作用较嘌呤类似物弱。
  • MP总体耐受良好,但具有毛细血管渗漏综合征和溶血性尿毒症综合征等独特毒性。

关键数值与推荐

  • FDA批准MP用于至少接受过2线治疗(包括嘌呤类似物)失败的HCL。

临床怎么用

  • MP可用于至少2线治疗失败(含嘌呤类似物)的HCL患者。
  • 使用MP时需监测毛细血管渗漏综合征和溶血性尿毒症综合征。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Moxetumomab pasudotox (MP) is an immunotoxin that recently received US Food and Drug Administration (FDA) approval for the treatment of hairy cell leukemia (HCL) that has failed at least 2 prior lines of therapy, including a purine analog. MP is a recombinant immunotoxin that consists of an anti-CD22 immunoglobulin variable domain genetically joined to Pseudomonas exotoxin (PE38). Unlike most antibody-drug conjugates, which use a chemical linker, recombinant DNA techniques are used to produce MP. MP and its predecessor, BL22, were initially developed to treat non-Hodgkin lymphoma, acute lymphoblastic leukemia, and HCL. However, MP was found to be particularly effective in HCL due to the high level of CD22 cell-surface expression. The recent pivotal phase 3 trial of MP in relapsed/refractory HCL demonstrated a durable complete remission rate of 30%, and 85% of complete responders achieved minimal residual disease negativity, which is associated with improved disease-free survival outcomes in HCL. In addition to an exceptional depth of response, MP appears to be less immunosuppressive than purine analogs. MP is generally well tolerated but has unique toxicities, including capillary leak syndrome and hemolytic uremic syndrome, which are poorly understood. This review will encompass the preclinical and clinical development of MP, with particular attention to its current indication in HCL.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Lin AY, Dinner SN. Moxetumomab pasudotox for hairy cell leukemia: preclinical development to FDA approval. Blood Adv. 2019. PMID: 31594764. doi:10.1182/bloodadvances.2019000507

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。